Logo image of VYGR

VOYAGER THERAPEUTICS INC (VYGR) Stock Fundamental Analysis

NASDAQ:VYGR - US92915B1061 - Common Stock

3.36 USD
-0.04 (-1.18%)
Last: 8/29/2025, 8:00:02 PM
3.36 USD
0 (0%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VYGR. VYGR was compared to 547 industry peers in the Biotechnology industry. VYGR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VYGR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VYGR had negative earnings in the past year.
VYGR had a negative operating cash flow in the past year.
In multiple years VYGR reported negative net income over the last 5 years.
VYGR had negative operating cash flow in 4 of the past 5 years.
VYGR Yearly Net Income VS EBIT VS OCF VS FCFVYGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

VYGR has a Return On Assets of -33.51%. This is in the better half of the industry: VYGR outperforms 63.07% of its industry peers.
Looking at the Return On Equity, with a value of -44.25%, VYGR is in the better half of the industry, outperforming 68.56% of the companies in the same industry.
Industry RankSector Rank
ROA -33.51%
ROE -44.25%
ROIC N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
VYGR Yearly ROA, ROE, ROICVYGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYGR Yearly Profit, Operating, Gross MarginsVYGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VYGR has more shares outstanding
VYGR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VYGR Yearly Shares OutstandingVYGR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VYGR Yearly Total Debt VS Total AssetsVYGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.69, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VYGR (-0.69) is comparable to the rest of the industry.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.69
ROIC/WACCN/A
WACC9.68%
VYGR Yearly LT Debt VS Equity VS FCFVYGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

VYGR has a Current Ratio of 5.43. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a Current ratio (5.43) which is in line with its industry peers.
A Quick Ratio of 5.43 indicates that VYGR has no problem at all paying its short term obligations.
With a Quick ratio value of 5.43, VYGR perfoms like the industry average, outperforming 59.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.43
Quick Ratio 5.43
VYGR Yearly Current Assets VS Current LiabilitesVYGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -760.71%.
VYGR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -70.38%.
The Revenue has been decreasing by -5.18% on average over the past years.
EPS 1Y (TTM)-760.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)-70.38%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-82.42%

3.2 Future

VYGR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.08% yearly.
The Revenue is expected to decrease by -5.45% on average over the next years.
EPS Next Y-90.87%
EPS Next 2Y-15.8%
EPS Next 3Y-7.74%
EPS Next 5Y-4.08%
Revenue Next Year-66.69%
Revenue Next 2Y-16.95%
Revenue Next 3Y-9.06%
Revenue Next 5Y-5.45%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
VYGR Yearly Revenue VS EstimatesVYGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
VYGR Yearly EPS VS EstimatesVYGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VYGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYGR Price Earnings VS Forward Price EarningsVYGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYGR Per share dataVYGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as VYGR's earnings are expected to decrease with -7.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.8%
EPS Next 3Y-7.74%

More info and screens

0

5. Dividend

5.1 Amount

VYGR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (8/29/2025, 8:00:02 PM)

After market: 3.36 0 (0%)

3.36

-0.04 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners64.02%
Inst Owner Change-4.56%
Ins Owners0.92%
Ins Owner Change-0.32%
Market Cap186.38M
Analysts87.78
Price Target15.98 (375.6%)
Short Float %6.98%
Short Ratio4.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.03%
Min EPS beat(2)-15.73%
Max EPS beat(2)-6.33%
EPS beat(4)1
Avg EPS beat(4)-3.62%
Min EPS beat(4)-57.86%
Max EPS beat(4)65.43%
EPS beat(8)5
Avg EPS beat(8)77.88%
EPS beat(12)8
Avg EPS beat(12)94.87%
EPS beat(16)10
Avg EPS beat(16)73.79%
Revenue beat(2)0
Avg Revenue beat(2)-50.87%
Min Revenue beat(2)-53.19%
Max Revenue beat(2)-48.55%
Revenue beat(4)1
Avg Revenue beat(4)-15.39%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)103.06%
Revenue beat(8)5
Avg Revenue beat(8)78.95%
Revenue beat(12)8
Avg Revenue beat(12)106.81%
Revenue beat(16)9
Avg Revenue beat(16)71.86%
PT rev (1m)-2.08%
PT rev (3m)14.99%
EPS NQ rev (1m)3.94%
EPS NQ rev (3m)-25.49%
EPS NY rev (1m)0.08%
EPS NY rev (3m)0.08%
Revenue NQ rev (1m)-17.37%
Revenue NQ rev (3m)-55.29%
Revenue NY rev (1m)-22.12%
Revenue NY rev (3m)-39.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.38
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.77
BVpS4.4
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.51%
ROE -44.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.54%
Cap/Sales 5.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.43
Quick Ratio 5.43
Altman-Z -0.69
F-Score1
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-760.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y-90.87%
EPS Next 2Y-15.8%
EPS Next 3Y-7.74%
EPS Next 5Y-4.08%
Revenue 1Y (TTM)-70.38%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-82.42%
Revenue Next Year-66.69%
Revenue Next 2Y-16.95%
Revenue Next 3Y-9.06%
Revenue Next 5Y-5.45%
EBIT growth 1Y-3109.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.07%
EBIT Next 3Y-18.17%
EBIT Next 5Y-16.3%
FCF growth 1Y-226.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-220.52%
OCF growth 3YN/A
OCF growth 5YN/A